The Food and Drug Administration has given tentative approval to Alembic's rivaroxaban tablets in dosage strengths of 10 mg, 15 mg, and 20 mg. The product is the generic of Janssen’s Xarelto tablets, ...

(HealthDay News) — Rivaroxaban is associated with reduced risk of recurrent events among patients with venous thromboembolism in equipoise for continued anticoagulation, according to a study published ...

June 29, 2007 (Perugia, Italy) - Promising phase 2 results with the new oral direct factor Xa inhibitor anticoagulant rivaroxaban (Bayer) in the treatment of patients with deep vein thrombosis (DVT) ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- ...

LOS ANGELES, CA—Another real-world study has suggested that there may be differences among the non-vitamin K antagonist oral anticoagulants (NOACs) in terms of the risk of major bleeding. Among ...

WASHINGTON, DC (updated with commentary) — In patients with venous thromboembolism (VTE) who had completed 6 to 12 months of anticoagulation therapy but for whom it was uncertain as to whether ...

The use of a fixed-dose of rivaroxaban was safe and effective and resulted in an 82% relative risk reduction in the recurrence of venous thromboembolism in patients receiving the drug as part of a ...

The ROCKET-AF trial was designed as double-blind, double dummy trial comparing rivaroxaban (20 mg or 15 mg once a day) with warfarin (target INR of 2.0 to 3.0) for the prevention of stroke and ...

Therapeutic-dose anticoagulation primarily consisting of rivaroxaban (Xarelto; Bayer/Janssen), compared with standard thromboprophylaxis, does not improve outcomes in patients hospitalized with ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. (HealthDay News) — Subcutaneous injection of abelacimab results ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The main clinical effectiveness evidence ...